Wellcome Trust: RFP to develop a business plan for a sustainable clinical trial network

Dear All:

Just released today is an RFP (see text just below my signature) to develop a business plan for the design, funding, and implementation of a sustainable clinical trial network for developing new antibacterial agents. 

The core of this idea emerged in early 2016 based on debates about the potential value of a network focused on a specific infection (e.g., nosocomial pneumonia) in which a standing protocol randomized subjects to a well-accepted standard comparator (probably a carbapenem) or a rotating series of investigational agents. A group of us summarized the key elements of the idea in this 2016 paper in Clinical Infectious Diseases. Here’s a visual illustration of the concept:


Figure legend from the CID paper: Shown are 3 years in the life of a network. To start the network, a target infection is chosen, a standard protocol is prepared, and a widely registered excellent standard comparator (control A) is selected. After a brief run-in period, test drugs are flexibly added and removed from the network. A constant control arm (control A) is envisioned, but alternative controls can also be used as needed to address issues such as blinding (control B paired with test 2). Multiple agents can be in the network simultaneously. It is also assumed that data on control agents can be shared across drugs.

The goal of the network is to reliably provide sponsors with a data from a properly powered and designed non-inferiority study that would serve as the basis for registration. When combined with implementation by the sponsor of a separate MDR/XDR study, you have the essence of a Tier B trial program.

The network study would be implemented in UDR (Usual Drug Resistance) settings in which a standard comparator such as a carbapenem would be acceptable. Sharing of controls and elimination of study startup delays for each new drug are estimated to reduce cost and time by ~40% for drugs using the network. Continuity for sites and investigators is provided by the ongoing nature of the network.

First discussed in early 2016, it is exciting to see Wellcome taking the next step towards making this concept a reality! Contact details are provided below should you or a colleague be interested in taking up this challenge. Expressions of interest are due by 12 March.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Wellcome Trust RFP (Request for proposals)
We’re looking to commission an organisation or consortium with understanding of the development and operations of clinical trial networks.
This follows our report on the importance of clinical trial networks for antibiotic development, and how they should be developed.
The purpose of this commission is to develop a business plan for the design, funding and implementation of a sustainable clinical trial network for infectious diseases centred specifically on antibiotic development.
The network should be able to:

  • generate comparative data on new agents quickly and efficiently
  • evaluate more than one investigational agent at a time using a standardised master protocol for each infection.

Our aim is that the findings from this work will inform the development of a new clinical trials network, helping to reduce costs, get clinical trials up and running more quickly, and lead to shorter late-stage trials.
Supporting documents, including a detailed timeline can be found on our website.
For more information or to express your interest, please email CTNetwork@wellcome.ac.uk. The deadline for expressing interest is Monday 12 March, 23:59 GMT.

Upcoming meetings of interest to the AMR community:


NIAID BAA – Biodefense focus / Fireside Chat on diagnostics and more

Dear All, We are swimming in Broad Agency Announcements aka BAAs! As a refresher, I recently shared a BAA from the CDC and one from BARDA — now we have another one from NIAID! There’s a strong biodefense angle here with lots of scope. Key details of each opportunity are as follows and I highly recommend you check

LPAD/Limited Use insights; NI margins for TB and candidiasis

Dear All,  I want to call your attention to next week’s AMDAC (Antimicrobial Drugs Advisory Committee) for rezafungin. This meeting is Tue 24 Jan 2023, 9a-4.30p ET and the meeting materials are provided here.  Rezafungin is an antifungal but please don’t let that dissuade you from attending: this AMDAC promises to be an important discussion

Notable webinars: Pediatric drug development; Drug delivery systems

Dear All, The high-value webinars below have just crossed my radar.  First up, we have a very important 2-part webinar on pediatric antibacterial drug development entitled “Improving the Investigation of New Antibacterial Agents for Use in Children: Ensuring That Our Youngest Patients Also Benefit from Innovative Treatments of Infections Caused by Multi-Drug Resistant Bacteria.” Here are the

CDC BAA: Surveillance, endpoints for decolonization, and more…

Dear All, Greetings in the new year! I just tonight picked up on this fascinating BAA (Broad Agency Announcement) from CDC: BAA 75D301-23-R-72545 as described on this general overview webpage: https://sam.gov/opp/15229982f7c348f69fd35e9a0add8aba/view The BAA itself  Timeline: Initial white papers (max 4 pages, see page 76 of the BAA for details) are due by 3 Feb 2023; Invitations for

Scroll to Top